If you've looked into therapy for depression, you've probably come across CBT — Cognitive Behavioural Therapy. It's the gold standard, and it works. But it's also complex, time-intensive, and requires a highly trained therapist. A major clinical trial called COBRA, published in 2016, tested whether a simpler approach might work just as well.
The simpler approach is called Behavioural Activation (BA). Instead of deep-diving into thought patterns, BA focuses on something more straightforward: getting you moving and re-engaged with activities that bring meaning or pleasure. Depression tends to pull you away from the things that make you feel good, which in turn makes the depression worse. BA helps interrupt that cycle.
The COBRA trial found that BA was just as effective as CBT for depression — similar outcomes, similar improvements, similar durability. And because BA doesn't require the same level of therapist training, it's more accessible and easier to deliver.
This matters because one of the biggest barriers to treating depression is simply access. People wait months for therapy, or can't afford it. Research like this opens the door to getting more people effective help, sooner.
If you're living with depression and wondering whether treatment is worth trying, the honest answer from the research is yes — and there are more good options than you might think. A psychologist can help you find the right fit.
What kind of study this actually is
COBRA is described as a randomised, controlled, non-inferiority trial. A randomised controlled trial (RCT) is a study where people are assigned by chance to different treatments, which helps rule out the possibility that differences in outcome are just due to who happened to end up in which group. 'Non-inferiority' is a specific and important design choice: instead of trying to prove that Behavioural Activation (BA) is *better* than Cognitive Behavioural Therapy (CBT), the trial is set up to test whether BA is *no worse* than CBT, within an acceptable margin. This is a sensible design when the new treatment isn't expected to outperform the established one on clinical grounds, but might have real advantages elsewhere — such as being simpler to deliver, cheaper, or requiring less specialist training.
What the study set out to do
The abstract frames the problem clearly: depression is common and costly, CBT has the strongest evidence base among psychological therapies, but it is complex and expensive to deliver well, since it requires therapists with substantial training. BA is proposed as a simpler alternative. Rather than working directly with thought patterns (a core feature of CBT), BA works on the observation that depression often leads people to withdraw from activities, relationships, and routines that used to feel rewarding or meaningful — and that this withdrawal itself maintains low mood. BA aims to reverse that cycle by systematically helping someone re-engage with valued activities, on the theory that mood follows behaviour as much as behaviour follows mood.
The stated aim of the COBRA trial was to establish both the clinical efficacy of BA compared with CBT (does it work as well, symptom-for-symptom?) and its cost-effectiveness (does it produce similar benefit for less money or fewer resources?). Cost-effectiveness matters clinically, not just financially, because a therapy that is cheaper to deliver can, in principle, reach more people, more quickly, within stretched health systems.
Why the comparison matters
If a simpler, less specialist-dependent therapy performs comparably to CBT, that has real implications for access. CBT's complexity means it can only be delivered well by therapists with lengthy training, which limits how many people can receive it and how quickly. BA, being more straightforward, could potentially be delivered by a wider range of practitioners after shorter training, which is one reason a non-inferiority design — rather than a straightforward superiority test — is the right tool here: the practical question isn't 'is BA better?' but 'is BA good enough, more efficiently?'
What this doesn't tell us
It's worth being precise about what the trial's stated aim covers and what it doesn't. It tells us the researchers set out to directly compare BA and CBT head-to-head in adults with depression, using a design suited to testing equivalence in outcome alongside cost. It doesn't, by itself, tell us anything about how either therapy compares to no treatment, medication, or other approaches, and comparative trials like this one are always specific to the populations and settings studied, so results don't automatically generalise to every context.
If any of this resonates with your own experience, it's worth talking to a psychologist about which approach might suit you — you don't have to figure it out alone.